Azenta 과거 순이익 실적
과거 기준 점검 0/6
Azenta은 연평균 11.8%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 연평균 3.8%의 비율로 감소했습니다. 매출은 연평균 9.3%의 비율로 증가했습니다.
핵심 정보
11.80%
순이익 성장률
-0.73%
주당순이익(EPS) 성장률
| Life Sciences 산업 성장률 | 21.51% |
| 매출 성장률 | 9.29% |
| 자기자본이익률 | -7.13% |
| 순이익률 | -18.59% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 25
AZTA: 2026 Guidance And Calibrated Expectations Will Support Sentiment Recovery
Analysts have reduced their price targets on Azenta by $10 and $5 in recent research. The updated fair value estimate of $26.20 reflects more cautious assumptions on revenue growth and profit margins, even as the projected future P/E edges higher.내러티브 업데이트 • May 01
AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery
Azenta's updated analyst price target has moved modestly lower by about $0.77, as analysts factor in refreshed assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research has focused on recalibrating Azenta's fair value, with several firms trimming their price targets by between $5 and $10 as they reassess assumptions for growth, profitability, and appropriate P/E levels.내러티브 업데이트 • Apr 15
AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery
Azenta's analyst price target has been trimmed by about $2.50 as analysts factor in updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research on Azenta points to a more cautious tone on valuation, with multiple price target trims clustering over a relatively short period.내러티브 업데이트 • Apr 01
AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery
Azenta's analyst price targets have been reduced by $5 to $9 in recent updates, as analysts factor in revised expectations for the diagnostic tools group and place greater emphasis on 2026 guidance and the clarity of the company's multi year growth framework. Analyst Commentary Recent research updates on Azenta show a mix of optimism around the long term framework and caution around the nearer term setup, with price targets adjusted both higher and lower as estimates and expectations are refreshed.Seeking Alpha • Mar 24
Azenta: Life Science Player Fails To Come To Life
Summary Azenta, Inc. trades near $20, with operating assets valued at just 0.5x sales and a robust net cash position around $600 million. Recent AZTA developments include the UK Biocentre acquisition and B Medical Systems divestiture, with the latter removing a key earnings drag. Despite a soft Q1 and margin pressure, Azenta maintains full-year guidance, supported by remediation efforts and interest income. The AZTA risk/reward is compelling at current levels, given low expectations, significant liquidity, and underappreciated asset value, making me a buyer despite above-average risks. Read the full article on Seeking Alpha내러티브 업데이트 • Mar 18
AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery
Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside. Analyst Commentary Bullish Takeaways Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.내러티브 업데이트 • Mar 03
AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery
Narrative Update: Azenta Azenta's latest analyst price targets have shifted slightly lower in recent research updates, with firms trimming their views by $5 and $9 after a prior increase to $39, as analysts factor in group wide adjustments in diagnostic tools and place more weight on visibility into the company's multi year framework and 2026 guidance. Analyst Commentary Recent research updates on Azenta reflect a mix of optimism about the long term setup and caution around execution and visibility, especially as analysts refresh their views on the broader diagnostic tools group and Azenta's multi year framework.
새로운 내러티브 • Feb 25
Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook
Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Feb 17
AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside
Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.
새로운 내러티브 • Feb 08
Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift
Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Feb 03
AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential
Analysts have nudged up their Azenta targets, with one moving to US$39 and another to US$45. This reflects interest in the company’s multi year growth framework and expectations for mid single digit organic revenue trends, with a path to margins above 20%.내러티브 업데이트 • Jan 20
AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward
Analysts have lifted their price target on Azenta to about US$43.50 from roughly US$40.17, citing slightly lower revenue growth expectations, firmer profit margin assumptions and a modestly lower future P/E outlook. The revised target is supported by recent research that notes improving sentiment, mid single digit organic revenue ambitions and a path to higher margins into 2026.내러티브 업데이트 • Jan 05
AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential
Analysts have nudged their fair value estimate for Azenta slightly higher to about $40, reflecting updated price targets in the mid to high $30s and low $40s, and their view that organic revenue growth and margin expansion potential into 2026 support a more constructive outlook on the shares. Analyst Commentary Recent research updates highlight a more constructive tone on Azenta, with several firms lifting price targets and turning more positive after the latest fiscal Q4 report and ahead of the upcoming investor day.내러티브 업데이트 • Dec 14
AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion
Azenta's analyst price target has been raised by $10 to $45, as analysts point to mid single digit plus organic revenue growth prospects and a credible path to margins above 20% that is supported by healthy biopharma exposure and multiple growth drivers into 2026. Analyst Commentary Bullish analysts highlight that the latest results, while largely in line with expectations, reinforce confidence in Azenta's ability to sustain mid single digit plus organic revenue growth while steadily expanding margins above 20% over the medium term.내러티브 업데이트 • Nov 29
AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026
Azenta's analyst price target has increased from $35.17 to $39.83. Analysts cite in-line financial results and ongoing optimism around revenue growth and expanding profit margins, supported by sector exposure and long-term innovation opportunities.분석 기사 • Nov 28
Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye
Investors signalled that they were pleased with Azenta, Inc.'s ( NASDAQ:AZTA ) most recent earnings report. Looking...내러티브 업데이트 • Nov 14
AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity
Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.내러티브 업데이트 • Oct 30
AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026
Azenta's analyst price target has been raised from $33 to approximately $35.17 per share. Analysts cite increased confidence in the company's growth drivers and mid-term opportunities, particularly within the biopharma sector.분석 기사 • Sep 12
Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?
While Azenta, Inc. ( NASDAQ:AZTA ) might not have the largest market cap around , it saw a decent share price growth of...분석 기사 • Aug 07
Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
NasdaqGS:AZTA 1 Year Share Price vs Fair Value Explore Azenta's Fair Values from the Community and select yours It's...분석 기사 • Jul 24
Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
Key Insights Azenta's estimated fair value is US$38.26 based on 2 Stage Free Cash Flow to Equity Current share price of...새로운 내러티브 • May 28
Pharma And Biotech Outsourcing Will Shape Future Market Dynamics
Strong industry trends and Azenta's infrastructure investments are driving above-market growth, recurring revenues, and operating leverage in sample management and biobanking.Seeking Alpha • Apr 17
Azenta: Life Science Business Failing To Come To Life
Summary Azenta, formerly Brooks Automation, has struggled to show organic growth and profitability, leading to a significant drop in its stock price. Despite a strong balance sheet and reduced valuation, the company needs to deliver real margin growth and profitability to attract investors. The company has faced challenges, including a decline in organic sales and the departure of its CEO, but continues to make strategic moves like selling B Medical Systems. Given the compressed sales multiples and strong cash position, a speculative position might be warranted, but management must prove its ability to improve earnings. Read the full article on Seeking Alpha분석 기사 • Apr 05
Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk
Unfortunately for some shareholders, the Azenta, Inc. ( NASDAQ:AZTA ) share price has dived 29% in the last thirty...분석 기사 • Mar 28
Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Azenta fair value estimate is US$70.94 Current share price of...Seeking Alpha • Jan 27
Azenta: Taking A Pass
Summary Azenta, Inc. shares have surged over 30% since Nov 2024 due to S&P 600 inclusion and an analyst upgrade, despite somewhat tepid growth prospects. The company is restructuring to save $30-$40 million by FY26, divesting a business segment, and has a strong balance sheet. An analysis on Azenta, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Jan 10
At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?
Azenta, Inc. ( NASDAQ:AZTA ), is not the largest company out there, but it received a lot of attention from a...분석 기사 • Dec 20
A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)
Key Insights The projected fair value for Azenta is US$56.65 based on 2 Stage Free Cash Flow to Equity With US$49.50...분석 기사 • Nov 17
Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%
The analysts covering Azenta, Inc. ( NASDAQ:AZTA ) delivered a dose of negativity to shareholders today, by making a...분석 기사 • Nov 14
Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price
It's not a stretch to say that Azenta, Inc.'s ( NASDAQ:AZTA ) price-to-sales (or "P/S") ratio of 3.1x right now seems...Seeking Alpha • Sep 11
Azenta: Life Science Play Is Not Coming To Life
Summary Azenta, Inc., formerly Brooks Automation, has struggled after the sale of its semiconductor business, as the remaining life sciences business has failed to turn a profit. Following aggressive share buybacks, Azenta's valuation remains demanding, with high earnings multiples and significant discrepancies between GAAP and non-GAAP earnings. New CEO John Marotta brings industry experience, but immediate results are unlikely, as the company needs to improve its margin profile and organic growth. I remain cautious on Azenta, monitoring its progress under new leadership, despite the seemingly low sales multiple and strong revenue base. Read the full article on Seeking Alpha분석 기사 • Jul 19
Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon
When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Azenta가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 596 | -111 | 250 | 34 |
| 31 Dec 25 | 595 | 26 | 252 | 32 |
| 30 Sep 25 | 594 | 24 | 262 | 30 |
| 30 Jun 25 | 586 | -27 | 261 | 31 |
| 31 Mar 25 | 586 | -28 | 264 | 31 |
| 31 Dec 24 | 579 | -24 | 263 | 31 |
| 30 Sep 24 | 573 | -24 | 263 | 32 |
| 30 Jun 24 | 595 | -21 | 273 | 31 |
| 31 Mar 24 | 616 | -23 | 284 | 33 |
| 31 Dec 23 | 628 | -9 | 289 | 34 |
| 30 Sep 23 | 551 | -8 | 264 | 32 |
| 30 Jun 23 | 630 | -21 | 302 | 33 |
| 31 Mar 23 | 597 | -26 | 285 | 30 |
| 31 Dec 22 | 594 | -25 | 279 | 29 |
| 30 Sep 22 | 555 | -11 | 251 | 28 |
| 30 Jun 22 | 555 | -28 | 267 | 26 |
| 31 Mar 22 | 551 | -23 | 267 | 25 |
| 31 Dec 21 | 535 | -29 | 261 | 24 |
| 30 Sep 21 | 514 | -29 | 252 | 22 |
| 30 Jun 21 | 114 | -69 | 183 | -10 |
| 31 Mar 21 | 205 | -53 | 185 | -2 |
| 31 Dec 20 | 296 | -37 | 183 | 9 |
| 30 Sep 20 | 389 | -26 | 190 | 18 |
| 30 Jun 20 | 850 | 41 | 232 | 59 |
| 31 Mar 20 | 834 | 28 | 224 | 59 |
| 31 Dec 19 | 812 | 16 | 217 | 58 |
| 30 Sep 19 | 334 | -61 | 157 | 17 |
| 30 Jun 19 | 741 | 3 | 194 | 54 |
| 31 Mar 19 | 710 | 7 | 182 | 51 |
| 31 Dec 18 | 668 | 72 | 170 | 49 |
| 30 Sep 18 | 632 | 68 | 163 | 47 |
| 30 Jun 18 | 488 | 35 | 154 | 41 |
| 31 Mar 18 | 498 | 47 | 149 | 40 |
| 31 Dec 17 | 510 | -2 | 146 | 40 |
| 30 Sep 17 | 527 | 11 | 141 | 40 |
| 30 Jun 17 | 669 | 56 | 136 | 46 |
| 31 Mar 17 | 634 | 47 | 132 | 47 |
| 31 Dec 16 | 600 | -51 | 127 | 49 |
| 30 Sep 16 | 434 | -85 | 116 | 44 |
| 30 Jun 16 | 549 | -73 | 123 | 52 |
| 31 Mar 16 | 546 | -74 | 119 | 52 |
| 31 Dec 15 | 550 | 12 | 117 | 52 |
| 30 Sep 15 | 553 | 14 | 114 | 52 |
| 30 Jun 15 | 529 | 8 | 112 | 53 |
양질의 수익: AZTA 은(는) 현재 수익성이 없습니다.
이익 마진 증가: AZTA는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: AZTA는 수익성이 없지만 지난 5년 동안 연평균 11.8%의 속도로 손실을 줄였습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 AZTA의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: AZTA은 수익성이 없어 지난 해 수익 성장률을 Life Sciences 업계(3.8%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: AZTA는 현재 수익성이 없으므로 자본 수익률이 음수(-7.13%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/27 10:27 |
| 종가 | 2026/05/27 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/09/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Azenta, Inc.는 15명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Christopher Muse | Barclays |
| Brett Hodess | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |